Navigation Links
Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
Date:3/18/2009

SAN FRANCISCO, March 18 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it has received written permission from the U.S. Food and Drug Administration (FDA) to begin a pivotal Phase 3 trial of MDV3100, its novel androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed docetaxel-based chemotherapy. The placebo-controlled, double-blind, multinational trial will enroll approximately 1,200 patients who will be randomized (2:1) to receive either MDV3100 or placebo. The primary endpoint of the trial will be overall survival.

"This is a significant milestone in the development of this important novel investigational drug," said David T. Hung, M.D., president and chief executive officer of Medivation. "We look forward to starting the trial and rapidly executing a comprehensive Phase 3 development program for MDV3100. Given the encouraging results seen to date in our ongoing Phase 1-2 trial and the limited life expectancy of men with CRPC who have failed chemotherapy, we will work to begin the Phase 3 clinical development of MDV3100 as quickly as possible this year."

The FDA informed the Company that it could test a dose of MDV3100 up to 240mg/day. There are no driving or other restrictions placed on the activities of participants in the trial. Final trial specifics will be announced when the first patient is enrolled.

MDV3100 Ongoing Phase 1-2 Trial

MDV3100 is being evaluated in an ongoing open-label, U.S., Phase 1-2 study of a total of 140 men with CRPC. Patients in this trial were heavily pretreated, with all having failed standard hormonal therapies and many having also failed docetaxel-based chemotherapy. MDV3100 has consistently demonstrated encouraging anti-tumor activity across dose levels and endpoints
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
2. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
5. Medivation Announces Participation in Upcoming Conferences
6. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
7. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
8. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
9. Urban Health Plan Receives $1.3M from Economic Stimulus Package to Increase Health Care Access in Corona, Queens
10. CUREXO Technology Corporation Receives Quality Certificate
11. Silk Information Systemss Silk V 4.2 Receives 08 CCHIT Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Reinberg HealthDay Reporter FRIDAY, ... should reassure the millions of American women who have migraine: ... "There is no association between migraine and breast cancer ... medicine at Harvard Medical School. "There is no positive association, ... no protective effect either." About 18 percent of American ...
(Date:12/15/2014)... December 15, 2014 The increase in prevalence ... of the main factors which is contributing to the growth ... the diagnosis and treatment of hearing loss and balance disorders ... three parts - microphone, speaker and amplifier. The global market ... of 6.01% during the period from 2014 to 2019. Some ...
(Date:12/15/2014)... 15, 2014 Emergo Group, Inc., a ... countries in North and South America, Europe, the Middle ... industry participants for its 2015 Medical Device Industry Survey. ... identify upcoming business and market trends as well as ... survey targets areas including:, , Overall ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 At the ... organizations AutismOne and Focus Autism ... attendees with research on the effects of toxins to ... and intervention information. , Luminaries such as Dr. ... from abroad with esteemed, credentialed colleagues of the United ...
(Date:12/15/2014)... Kenmode Precision Metal Stamping has announced that Abid ... Assurance. He brings more than 15 years of ... manufacturers in the U.S. and abroad. , He ... Sonoco Products Company in the Protective Solutions Division, Vice ... Manager for Prince Industries, all in the Chicago area. ...
Breaking Medicine News(10 mins):Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2
... CVS Caremark (NYSE: CVS ) announced ... again been recognized for customer satisfaction excellence by ... This is the third time that the Company ... center operations as providing "An Outstanding Customer Service ...
... CYBX ) today announced that the company will ... 2009 of its fiscal year ending April 24, 2009 on ... company will conduct a conference call to discuss those results ... Fiscal Year 2009 Third Quarter Results Conference Call Instructions ...
... Workouts counter functional decline, could ward off osteoarthritis, ... News) -- Exercise may play a key role ... and knee osteoarthritis (OA), two new studies show. ... following a six-week progressive strengthening program showed much ...
... cause of death with over 6 million new cases worldwide ... of cancer are diagnosed annually, and half a million Americans ... years of research, GlycoMeds ( http://www.cancer-test-kits.com ) has released the ... a way to detect it in the early stages when ...
... investigation into the shooting death of American video-journalist Brad Will has ... the discovery that one of the bullets was a ricochet. ... ... Physicians for Human Rights (PHR) charges that Mexico,s investigation into ...
... Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to ... 4 Decision Resources, one of the world,s ... healthcare issues, finds that an oral disease-modifying therapy ... percent patient share in Europe and a 40 ...
Cached Medicine News:Health News:Caremark Customer Care Centers Recognized for Customer Satisfaction Excellence by J.D. Power and Associates Certified Call Center Program(SM) 2Health News:Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Third Quarter Financial Results 2Health News:Exercise Key Player in Knee Replacement Recovery 2Health News:GlycoMeds Discovery Yields Early Warning Test for Cancer 2Health News:Mexico Presents Flawed Theory in Shooting Death of American Journalist 2Health News:Mexico Presents Flawed Theory in Shooting Death of American Journalist 3Health News:Mexico Presents Flawed Theory in Shooting Death of American Journalist 4Health News:An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the United States 2Health News:An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the United States 3
(Date:12/17/2014)... SCOTTSDALE, Ariz. , Dec. 17, 2014 /PRNewswire/ ... of state-of-the-art interactive music products, today announced that ... Ltd, a leading manufacturer and supplier of innovative ... As part of the agreement, RSL ... Facility bundled solution specifically configured for use within ...
(Date:12/17/2014)... KENNESAW, Ga. and RALEIGH, ... Clinical Trial Marketing Communications, LLC (CTMC), and Integrated ... in patient recruitment and retention for clinical trials ... called Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS ... and retention services to pharmaceutical, biotechnology and medical ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Inferior Vena Cava (IVC) Filters - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... projected to reach US$435 million by 2016. The ... (2015) of the global value while Europe ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4